Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker(University of Ottawa), Malcolm J. Moore(University Health Network), Chris J. O’Callaghan(Unknown), Guy van Hazel(Sir Charles Gairdner Hospital), Marianne Krahn(St. Boniface Hospital), Timothy Price(Basil Hetzel Institute), Dongsheng Tu(Ontario Institute for Cancer Research), Christos S. Karapetis(Clínica Alemana), R. J. Simes(The University of Sydney), Niall C. Tebbutt(Austin Health), Scott Berry, Christiane Langer(Bristol-Myers Squibb (United States)), John Zalcberg(Monash Health)
Cited by 1,806
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k